Indicatie
Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
In andere landen
Dezelfde werkzame stoffen in andere registers, met hetzelfde merk eerst.
Nationale vermeldingen
De nationale registers waarin dit EU-geneesmiddel staat.